Ascendis Pharma (ASND) Tops Q1 EPS by 68c

Ascendis Pharma (NASDAQ: ASND) reported Q1 EPS of (EUR1.98), EUR0.68 better than the analyst estimate of (EUR2.66). Revenue for the quarter came in at EUR28.97 million versus the consensus estimate of EUR21.15 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Verizon to cut 3,000 jobs as it shifts stores to franchises
• DBV Technologies (DBVT) Misses Q2 EPS by 12c
• F.N.B. Corp (FNB) Reports In-Line Q2 EPS